Видео ютуба по тегу Biovie

BioVie advances Parkinson’s, long COVID, and liver disease programs ahead of 2026
BioVie advances Parkinson’s, long COVID, and liver disease programs ahead of 2026
BioVie Targets Alzheimer’s, Parkinson’s & Long COVID With Metabolic Anti-Inflammatory Therapy
BioVie Targets Alzheimer’s, Parkinson’s & Long COVID With Metabolic Anti-Inflammatory Therapy
One Mechanism, Three Conditions: A New Direction in Neurological Treatment
One Mechanism, Three Conditions: A New Direction in Neurological Treatment
L’art de vivre sain sans austérité : une nouvelle vision de la détox, joyeuse et vivante 📱
L’art de vivre sain sans austérité : une nouvelle vision de la détox, joyeuse et vivante 📱
L’art de vivre sain sans austérité : une nouvelle vision de la détox, joyeuse et vivante
L’art de vivre sain sans austérité : une nouvelle vision de la détox, joyeuse et vivante
How Authenticity Changes Everything - Interview Eric Viard manager of biovie.fr by Myla Adamsha
How Authenticity Changes Everything - Interview Eric Viard manager of biovie.fr by Myla Adamsha
BioVie AGM 2025 | Nov 10, 2025
BioVie AGM 2025 | Nov 10, 2025
BioVie (NASDAQ: BIVI) продвигает исследования по лечению болезни Паркинсона и длительной COVID-19
BioVie (NASDAQ: BIVI) продвигает исследования по лечению болезни Паркинсона и длительной COVID-19
RedChip Highlights Nexalin Technology, Inc. (NASDAQ: NXL) & BioVie (NASDAQ: BIVI)
RedChip Highlights Nexalin Technology, Inc. (NASDAQ: NXL) & BioVie (NASDAQ: BIVI)
Joseph Palumbo, Head of R&D & Chief Medical Officer at BioVie Inc
Joseph Palumbo, Head of R&D & Chief Medical Officer at BioVie Inc
BioVie Investor Webinar and Q&A | Oct 08, 2025
BioVie Investor Webinar and Q&A | Oct 08, 2025
RedChip Investor Webinar with BioVie (Nasdaq: BIVI)
RedChip Investor Webinar with BioVie (Nasdaq: BIVI)
BioVie CEO Cuong Do on Phase 3 Strategy & Market Potential in CNS and Liver Disease
BioVie CEO Cuong Do on Phase 3 Strategy & Market Potential in CNS and Liver Disease
BioVie: Big Clinical Opportunities Ahead in 2025 | 30 Second Overview
BioVie: Big Clinical Opportunities Ahead in 2025 | 30 Second Overview
My Take on BioVie's Rollercoaster Annual Report
My Take on BioVie's Rollercoaster Annual Report
BioVie Raises $12M in Public Offering to Advance Liver & Neurological Therapies
BioVie Raises $12M in Public Offering to Advance Liver & Neurological Therapies
BioVie Raises $12M in Public Offering to Advance Liver & Neurological Therapies
BioVie Raises $12M in Public Offering to Advance Liver & Neurological Therapies
BIVI, FGF, RCEL, SRTS & IOVA - Stocks on the Dip
BIVI, FGF, RCEL, SRTS & IOVA - Stocks on the Dip
BioVie Targets Parkinson’s & Long COVID - DNA Age Reversal & Inflammation Insights
BioVie Targets Parkinson’s & Long COVID - DNA Age Reversal & Inflammation Insights
Vos questions sur la plaque mucoide : Zencleanz x Biovie
Vos questions sur la plaque mucoide : Zencleanz x Biovie
A Huge Risk I See in BioVie's New Filing
A Huge Risk I See in BioVie's New Filing
BioVie’s Breakthrough in Alzheimer’s, Parkinson’s & Long COVID
BioVie’s Breakthrough in Alzheimer’s, Parkinson’s & Long COVID
Alzheimer’s Breakthrough: Biovie Unveils Age-Reversing Drug Bezisterum | NewsOut
Alzheimer’s Breakthrough: Biovie Unveils Age-Reversing Drug Bezisterum | NewsOut
Alzheimer’s Breakthrough: Biovie Unveils Age-Reversing Drug Bezisterum | NewsOut
Alzheimer’s Breakthrough: Biovie Unveils Age-Reversing Drug Bezisterum | NewsOut
Biovie à Maison Chance à Ho Chi Minh, Vietnam
Biovie à Maison Chance à Ho Chi Minh, Vietnam